OncoMatch/Clinical Trials/NCT06897046
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Is NCT06897046 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including QL1706 and QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed for non-small cell lung cancer (nsclc).
Treatment: QL1706 · QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed — This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR positive mutation
Presence of confirmed EGFR or ALK positive mutations
Excluded: ALK positive mutation
Presence of confirmed EGFR or ALK positive mutations
Disease stage
Required: Stage II, IIIA, IIIB (N2 ONLY) (AJCC 8th edition)
Stage II-IIIB (N2 only) non-small cell lung cancer (NSCLC) according to the 8th edition of the American Joint Committee on Cancer (AJCC). Only patients judged as T4 based on tumor size are allowed to be enrolled; other T4 conditions (e.g., invasion of the diaphragm, mediastinal involvement) are not permitted.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06897046 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR positive mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK positive mutation is an exclusion criterion.
What disease stage is eligible?
Stage II or IIIA or IIIB (N2 ONLY) is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages